PMID- 11402619
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20190921
IS  - 0023-5679 (Print)
IS  - 0023-5679 (Linking)
VI  - 48
IP  - 1
DP  - 2001
TI  - Vascular endothelial growth factor (VEGF) serum concentration changes during 
      chemotherapy in patients with lung cancer.
PG  - 43-7
AB  - Vascular endothelial growth factor (VEGF) is one of the most important angiogenic 
      factors. This study aimed at clarifying the clinical significance of the changes 
      in the serum VEGF (S-VEGF) concentrations in patients with lung cancer during 
      anticancer chemotherapy. Subjects comprised 29 patients with lung cancer (13 
      adenocarcinomas, 7 squamous cell carcinomas, and 9 small cell carcinomas) who 
      were treated with cisplatin-based chemotherapy. S-VEGF was measured by ELISA. We 
      compared the S-VEGF concentrations between the responders and nonresponders to 
      anticancer chemotherapy. S-VEGF concentrations before treatment of the 
      chemotherapy (pretreatment S-VEGF concentrations) were correlated with the number 
      of WBC, neutrophil count, monocyte count and platelet count but not the 
      lymphocyte count. The mean pretreatment S-VEGF concentrations in responders and 
      those in nonresponders were not significantly different, 509.7 pg/ml in the 
      former and 382.8 pg/ml in the latter, respectively., The S-VEGF concentrations in 
      the responders decreased to a mean of 356.0 pg/ml and 304.1 pg/ml during and at 
      the end of therapy, respectively while those in the nonresponders increased to a 
      mean of 474.2 pg/ml and 598.4 pg/ml during and at the end of therapy. The S-VEGF 
      concentration changes in the responders were significantly different from those 
      in the nonresponders (p = .006). The S-VEGF concentration may relate to tumor 
      burden, however it may not be a good marker for tumor burden, because it can be 
      influenced by various factors such as neutrophil which increases during 
      infection. A decrease in S-VEGF concentrations may improve neoangiogenesis and 
      the immune response, and may correlate with improvements in the quality of life 
      and survival of patients.
FAU - Kido, Y
AU  - Kido Y
AD  - Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 
      Kurume 830-0011, Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Kurume Med J
JT  - The Kurume medical journal
JID - 2985210R
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Lymphokines)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Endothelial Growth Factors/*blood
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/blood/*drug therapy/mortality
MH  - Lymphokines/*blood
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
EDAT- 2001/06/14 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/06/14 10:00
PHST- 2001/06/14 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/06/14 10:00 [entrez]
AID - 10.2739/kurumemedj.48.43 [doi]
PST - ppublish
SO  - Kurume Med J. 2001;48(1):43-7. doi: 10.2739/kurumemedj.48.43.